Curis, Inc.

The company is a biotechnology company focused on developing emavusertib (CA-4948), an oral, small molecule inhibitor targeting Interleukin-1 receptor associated kinase (IRAK4) and FMS-like tyrosine kinase 3 (FLT3). Emavusertib is currently being studied in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) for patients with relapsed/refractory primary central nervous system lymphoma (PCNSL), where it is combined with ibrutinib, a Bruton Tyrosine Kinase (BTK) inhibitor. It is also being evaluated in the recently started TakeAim CLL study, a Phase 2 combination study for chronic lymphocytic leukemia (CLL) with zanubrutinib, another BTK inhibitor. The company's monotherapy and combination studies of emavusertib in acute myeloid leukemia (AML) are largely complete. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for treating PCNSL, AML, and myelodysplastic syndromes (MDS), and from the European Commission for treating PCNSL. The company holds the exclusive license to emavusertib (CA-4948) through a 2015 collaboration with Aurigene Discovery Technologies Limited. As of December 31, 2025, the company had $5.1 million in cash and cash equivalents. In January 2026, it completed a private placement, the January 2026 PIPE Financing, which generated net proceeds of approximately $18.6 million.